Trial · NCT01003275

Metabolic Effects of Paricalcitol

NCT01003275, Phase 2, Completed, University of Washington; results first posted 2013-09-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Metabolic Effects of Paricalcitol. Trials, record NCT01003275. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01003275

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Metabolic Effects of Paricalcitol
NCT number: NCT01003275
Status: Completed
Phases: Phase 2
Enrollment: 22 participants, actual
Lead sponsor: University of Washington
Conditions: Chronic Kidney Disease
Interventions: Paricalcitol, Placebo
First posted: 2009-10-28
Last updated: 2014-04-28
Results first posted: 2013-09-27

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Glucose Area Under the Curve (AUC)	8 weeks	Glucose AUC during a 2-hour oral glucose tolerance test

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Glucose Area Under the Curve (AUC)	8 weeks		mg*min/dL	GEOMETRIC_MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Glucose Area Under the Curve (AUC)	During Paricalcitol Treatment		20817	Geometric Coefficient of Variation 1.2	mg*min/dL
Glucose Area Under the Curve (AUC)	During Placebo Treatment		21139	Geometric Coefficient of Variation 1.2	mg*min/dL

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Paricalcitol Followed by Placebo	11
Overall Study	STARTED	Placebo Followed by Paricalcitol	11
Overall Study	COMPLETED	Paricalcitol Followed by Placebo	10
Overall Study	COMPLETED	Placebo Followed by Paricalcitol	11
Overall Study	NOT COMPLETED	Paricalcitol Followed by Placebo	1
Overall Study	NOT COMPLETED	Placebo Followed by Paricalcitol	0

Source ClinicalTrials.gov

Adverse events38

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypercalcemia	Endocrine disorders	During/After Paricalcitol	1	22	1
other	Hypercalcemia	Endocrine disorders	During/After Placebo	0	21	0
other	Elevated serum creatinine	Metabolism and nutrition disorders	During/After Paricalcitol	1	22	1
other	Elevated serum creatinine	Metabolism and nutrition disorders	During/After Placebo	0	21	0
other	Fistula placement	Metabolism and nutrition disorders	During/After Paricalcitol	1	22	1
other	Fistula placement	Metabolism and nutrition disorders	During/After Placebo	0	21	0
other	Renal artery stent	Metabolism and nutrition disorders	During/After Paricalcitol	1	22	1
other	Renal artery stent	Metabolism and nutrition disorders	During/After Placebo	0	21	0
other	Dyspnea with palpitations and lightheadedness	Cardiac disorders	During/After Paricalcitol	1	22	1
other	Dyspnea with palpitations and lightheadedness	Cardiac disorders	During/After Placebo	0	21	0

1 to 10 of 38Source ClinicalTrials.gov

See all 38 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	During/After Paricalcitol
Total, all-cause mortality	During/After Placebo
Total, other adverse events	During/After Paricalcitol	10	22
Total, other adverse events	During/After Placebo	7	21
Total, serious adverse events	During/After Paricalcitol	0	22
Total, serious adverse events	During/After Placebo	0	21

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22913981	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
During/After Paricalcitol vs During/After Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01003275

GET https://conductscience.org/api/trials/v1/NCT01003275/events?page=2

API reference For AI assistants